Galapagos NV
Formerly | Galapagos Genomics NV |
---|---|
Type | Naamloze vennootschap |
Euronext: GLPG Nasdaq: GLPG BEL 20 component AEX component | |
Industry | Pharmaceutical |
Founded | 1999 |
Headquarters | Mechelen, Belgium |
Key people | Onno van de Stolpe (CEO), Raj Parekh (Chairman) |
Products | filgotinib; GLPG1205; GLPG0778 |
Revenue | €288.836 million (2018)[1] |
€-29.259 million (2018)[1] | |
Total assets | €1,439.496 million (2018)[1] |
Total equity | €1,214.249 million (2018)[1] |
Number of employees | 725 (2018)[1] |
Website | www |
Galapagos NV (formerly known as Galapagos Genomics) is a Belgian pharmaceutical research company which was founded in 1999. Its headquarters are located in Mechelen and has additional locations in Leiden, Romainville, Basel, Milan, Madrid, Boston and Zagreb. The CEO is the Dutchman Onno van de Stolpe.
The company develops drugs against rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, systemic lupus erythematosus and cystic fibrosis.[2]
History[]
Galapagos Genomics NV was founded in 1999 as a joint venture between Crucell and Tibotec.[3] The company later changed its name to Galapagos NV and completed its initial public offering on Euronext Amsterdam and Euronext Brussels in May 2005.[4]
The company uses a technological platform for its research, which is based on adenoviruses to introduce human gene sequences into a wide variety of human cell lines to knock-in or knock-down specific proteins.
In 2019, Gilead Sciences and Galapagos entered into transformative research and development collaboration. Gilead and Galapagos have also agreed to amend certain terms around the development and commercialization of filgotinib.[5]
Drugs currently under development[]
- Filgotinib (GLPG0634) a selective inhibitor of JAK1 (Janus kinase 1) being developed for the treatment of rheumatoid arthritis and potentially Crohn's disease.
- : a first-in-class GPR84-inhibitor currently under research for the treatment of inflammatory bowel disease.
See also[]
References[]
- ^ Jump up to: a b c d e "Galapagos Annual Report 2018". Galapagos.
- ^ Todd Campbel (9 June 2016). "Why Galapagos NV Shares Soared 30.5% in May". The Motley Fool.
- ^ "History". Galapagos.
- ^ "Galapagos Genomics gaat zelf medicijnen ontwikkelen" [Galapagos Genomics to develop medicines themselves]. Het Nieuwsblad (in Dutch). 16 April 2005.
- ^ Gilead and Galapagos Enter Into Transformative Research and Development Collaboration, PM Gilead July 14, 2019, Retrieved 2020-05-09
External links[]
- Companies in the BEL 20
- Belgian brands
- Pharmaceutical companies of Belgium
- Pharmaceutical companies established in 1999
- Companies listed on Euronext Amsterdam
- Companies listed on the Nasdaq
- Companies based in Antwerp (province)
- 1999 establishments in Belgium